Fyn promotes proliferation, differentiation, survival and function of osteoclast lineage cells

c‐Src and Lyn are the only Src family kinases (SFKs) with established activity in osteoclasts (OCs). c‐Src promotes function via cytoskeletal organization of the mature resorptive cell while Lyn is a negative regulator of osteoclastogenesis. We establish that Fyn, another SFK, also impacts the OC, but in a manner distinctly different than c‐Src and Lyn. Fyn deficiency principally alters cells throughout the osteoclastogenic process, resulting in diminished numbers of resorptive polykaryons. Arrested OC formation in the face of insufficient Fyn reflects reduced proliferation of precursors, in response to M‐CSF and retarded RANK ligand (RANKL)‐induced differentiation, attended by suppressed activation of the osteoclastogenic signaling molecules, c‐Jun, and NF‐κB. The anti‐apoptotic properties of RANKL are also compromised in cells deleted of Fyn, an event mediated by increased Bim expression and failed activation of Akt. The defective osteoclastogenesis of Fyn−/− OCs dampens bone resorption, in vitro. Finally, while Fyn deficiency does not regulate basal osteoclastogenesis, in vivo, it reduces that stimulated by RANKL by ∼2/3. Thus, Fyn is a pro‐resorptive SFK, which exerts its effects by prompting proliferation and differentiation while attenuating apoptosis of OC lineage cells. J. Cell. Biochem. 111: 1107–1113, 2010. © 2010 Wiley‐Liss, Inc.

[1]  W. Zou,et al.  SLP-76 Couples Syk to the Osteoclast Cytoskeleton1 , 2009, The Journal of Immunology.

[2]  R. Faccio,et al.  The Src family kinase, Lyn, suppresses osteoclastogenesis in vitro and in vivo , 2009, Proceedings of the National Academy of Sciences.

[3]  W. Zou,et al.  DAP12 couples c-Fms activation to the osteoclast cytoskeleton by recruitment of Syk. , 2008, Molecular cell.

[4]  R. Faccio,et al.  RelA/p65 promotes osteoclast differentiation by blocking a RANKL-induced apoptotic JNK pathway in mice. , 2008, The Journal of clinical investigation.

[5]  R. Faccio,et al.  c-Fms Tyrosine 559 Is a Major Mediator of M-CSF-induced Proliferation of Primary Macrophages* , 2007, Journal of Biological Chemistry.

[6]  S. Teitelbaum Osteoclasts: what do they do and how do they do it? , 2007, The American journal of pathology.

[7]  J. Brewer,et al.  Glucocorticoids suppress bone formation via the osteoclast. , 2006, The Journal of clinical investigation.

[8]  F. Sánchez‐Madrid,et al.  Role of Fyn in the Rearrangement of Tubulin Cytoskeleton Induced through TCR1 , 2006, The Journal of Immunology.

[9]  Kozo Nakamura,et al.  Role of RANKL in physiological and pathological bone resorption and therapeutics targeting the RANKL–RANK signaling system , 2005, Immunological reviews.

[10]  R. Schüle,et al.  FHL2 inhibits the activated osteoclast in a TRAF6-dependent manner. , 2005, The Journal of clinical investigation.

[11]  T. Yagi,et al.  FcɛRI-mediated mast cell degranulation requires calcium-independent microtubule-dependent translocation of granules to the plasma membrane , 2005, The Journal of cell biology.

[12]  W. Swat,et al.  Vav3 regulates osteoclast function and bone mass , 2005, Nature Medicine.

[13]  K. Hruska,et al.  Akt1/Akt2 and Mammalian Target of Rapamycin/Bim Play Critical Roles in Osteoclast Differentiation and Survival, Respectively, Whereas Akt Is Dispensable for Cell Survival in Isolated Osteoclast Precursors* , 2005, Journal of Biological Chemistry.

[14]  Y. Kadono,et al.  Regulation of osteoclast apoptosis by ubiquitylation of proapoptotic BH3‐only Bcl‐2 family member Bim , 2003, The EMBO journal.

[15]  D. Goeddel,et al.  The IκB Function of NF-κB2 p100 Controls Stimulated Osteoclastogenesis , 2003, The Journal of experimental medicine.

[16]  S. Teitelbaum,et al.  Genetic regulation of osteoclast development and function , 2003, Nature Reviews Genetics.

[17]  Hong-Hee Kim,et al.  Signal transduction by receptor activator of nuclear factor kappa B in osteoclasts. , 2003, Biochemical and biophysical research communications.

[18]  Michael Karin,et al.  NF-κB in cancer: from innocent bystander to major culprit , 2002, Nature Reviews Cancer.

[19]  C. Print,et al.  The proapoptotic BH3-only protein bim is expressed in hematopoietic, epithelial, neuronal, and germ cells. , 2000, The American journal of pathology.

[20]  D L Lacey,et al.  Osteoprotegerin ligand modulates murine osteoclast survival in vitro and in vivo. , 2000, The American journal of pathology.

[21]  H. Hanafusa,et al.  TRANCE, a TNF family member, activates Akt/PKB through a signaling complex involving TRAF6 and c-Src. , 1999, Molecular cell.

[22]  E. Jimi,et al.  Osteoclast differentiation factor acts as a multifunctional regulator in murine osteoclast differentiation and function. , 1999, Journal of immunology.

[23]  Yongwon Choi,et al.  TRANCE Is Necessary and Sufficient for Osteoblast-mediated Activation of Bone Resorption in Osteoclasts , 1998, The Journal of experimental medicine.

[24]  S. Teitelbaum,et al.  Lipopolysaccharide-stimulated osteoclastogenesis is mediated by tumor necrosis factor via its P55 receptor. , 1997, The Journal of clinical investigation.

[25]  B. Druker,et al.  Regulation of Integrin-mediated p130Cas Tyrosine Phosphorylation in Human B Cells , 1997, The Journal of Biological Chemistry.

[26]  E R Kandel,et al.  Rescuing impairment of long-term potentiation in fyn-deficient mice by introducing Fyn transgene. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[27]  P. Maness,et al.  NCAM140 Interacts with the Focal Adhesion Kinase p125fak and the SRC-related Tyrosine Kinase p59fyn* , 1997, The Journal of Biological Chemistry.

[28]  Philippe Soriano,et al.  Knockouts of Src-family kinases: stiff bones, wimpy T cells, and bad memories. , 1996, Genes & development.

[29]  T. Yagi,et al.  Initial events of myelination involve Fyn tyrosine kinase signalling , 1994, Nature.

[30]  T. Yoneda,et al.  Requirement of pp60c-src expression for osteoclasts to form ruffled borders and resorb bone in mice. , 1992, The Journal of clinical investigation.

[31]  P. Stein,et al.  pp59 fyn mutant mice display differential signaling in thymocytes and peripheral T cells , 1992, Cell.

[32]  Allan Bradley,et al.  Targeted disruption of the c-src proto-oncogene leads to osteopetrosis in mice , 1991, Cell.

[33]  J. O’Shea,et al.  Fyn kinase initiates complementary signals required for IgE-dependent mast cell degranulation , 2002, Nature Immunology.

[34]  Michael Karin,et al.  NF-kappaB in cancer: from innocent bystander to major culprit. , 2002, Nature reviews. Cancer.

[35]  G. Rodan,et al.  Abnormal localisation and hyperclustering of (alpha)(V)(beta)(3) integrins and associated proteins in Src-deficient or tyrphostin A9-treated osteoclasts. , 2001, Journal of cell science.